Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 35 for “"CAR-T Cells"”.
-
TOX2 and TOX at the intersection of central memory and exhaustion in human CAR T cells
CAR T therapy has provided a breakthrough in the treatment of hematologic malignancies, showing remarkable efficacy in cancers such as leukemia and lymphoma. However, the success of CAR T therapy in treating solid tumors has been limited due to T cell exhaustion, which limits their proliferation …
-
A Novel, Codon-Based Approach to Preserve On-Tumor Activity and Reduce Off-Tumor Toxicity of Chimeric Antigen Receptor (CAR) T Cells
<p> Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable results in the treatment of various hematological malignancies, ushering in tremendous innovation within the field of immunotherapy and improving patient outcomes. Despite this, CAR-T cell therapy is associated with a …
-
Engineering VHH-based chimeric antigen receptor (CAR) T cell therapy for solid tumor treatment
Chimeric antigen receptor (CAR) T cells are a promising cancer therapeutic, as they can specifically redirect the cytotoxic function of a T cell to a chosen target of interest. CAR T cells have been successful in clinical trials against hematological cancers, but have experienced low efficacy …
-
Enhancing Chimeric Antigen Receptor T cell therapy in Mouse EGFRvIII Heterogeneous Glioblastoma
<p>Chimeric antigen receptor (CAR) T cell therapy for glioblastoma remains challenging due to insufficient CAR T cell abundance and antigen-negative tumor cells evading targeting. Unfortunately, most preclinical studies evaluating CAR T cells in glioblastoma use tumors expressing a single antigen, …
-
Generation of a novel pan-cancer chemokine receptor-modified CAR-T cell therapy directed towards nfP2X7
CAR-T cell therapy has achieved significant success in the treatment of multiple haematological malignancies. However, solid cancers present challenges such as tumour antigen heterogeneity and complex mechanisms of immune evasion that have limited the translation of CAR-T cell therapies from …
-
Tethered Il-15 to Augment The Therapeutic Potential of T Cells Expressing Chimeric Antigen Receptor: Maintaining Memory Potential, Persistence, and Antitumor Activity
… IL-15 to augment the therapeutic potential of T cells expressing chimeric antigen receptor: Maintaining memory potential, persistence, and antitumor activity</strong></p> <p>Adoptive immunotherapy can retarget T cells to CD19, a tumor-associated antigen (TAA) expressed on B-cell malignancies, by …
-
Characterizing T Cell Features of Atypical Lymphocytes for the Optimization of Adoptive Immunotherapies
… results. Two such populations are regulatory T cells (Tregs) and CAR (chimeric antigen receptor-modified) T cells. The functional role of Tregs in the immune system is non-canonical, in that they prevent hyper-inflammation and resolve immunopathology by constraining conventional immune cell …
-
In-vitro Glioblastoma Treatment Focusing on Convection Enhanced Delivery
… brain cancer with discouraging standard of care. New methods like convection enhanced delivery and chimeric antigen receptor T cells (CAR-T) are promising treatments that can be translated to glioblastoma. In this study, CAR-T cell flow through a hydrogel was explored in the context of …
-
Therapeutic Strategies to Target LILRB Receptors on Myeloid Cells for Cancer Immunotherapy
… patients with cancer. Immunosuppressive myeloid cells which inhibit anti-tumor immunity are recognized as one of the major obstacles in cancer treatment. LILRB3 and LILRB4, immune inhibitory receptors containing tyrosine-based inhibitory motifs (ITIMs), are expressed solely on myeloid cells. …
-
Development of a canine model to evaluate CAR-T cell subsets
… Immunotherapy with chimeric antigen receptor (CAR) T cells has demonstrated success in human blood cancers, although relapse occurs in ~50% of patients. In the context of solid tumors, CAR-T cells show only transient effects. As a "living therapy", development of the next generation CAR-T cells …
-
Mathematical Modelling of Immuno-Oncology and Related Immunology
… look specifically at Chimeric Antigen Receptor (CAR)-T cell therapy, explore the mechanisms by which this living drug grows and changes inside the body, and explore how and why this process differs so dramatically between patients. </p><p>We develop two ordinary differential equation models -- …
-
Employing T Cells For Antigen Presentation: Role of Ny-Eso-1+ T-Apc Vaccine In Multiple Myeloma
… clinical trials with persistence of effector cells appearing to lead to improved outcomes. Combined immunotherapy with NY-ESO-1<sup>+</sup> CAR T cells (TCR mimetic) and an NY-ESO-1 specific T-APC vaccine in myeloma patients may lead to enhanced anti-myeloma efficacy due to improved …
-
Targeting T Cells for the Immune-Modulation of Human Diseases
… executers and sentinels of host immunity, T cells represent a compelling target population for immune-modulation. In fact, the antigen-specificity, cytotoxicity and promise of long-lived of immune-protection make T cells ideal vehicles for cancer immunotherapy. Interventions for autoimmune …
-
Engineering of next-generation chimeric antigen receptors based on alternative binding domains
… expression of chimeric antigen receptors (CARs) on T lymphocytes (CAR-T) and NK cells (CAR-NK) has allowed the design of effective therapies against lymphoproliferative diseases and has recently achieved success against solid tumors. Given their success, several researchers set out to …
-
Leveraging Systems Immunology To Understand The Molecular Underpinnings Of Chimeric Antigen Receptor T-Cell Therapy
Chimeric Antigen Receptor (CAR) T-cell therapy is a promising strategy for the treatment of human cancers, and in the last decade has progressed from breakthrough early trials to first in class FDA approvals for B-cell leukemias and lymphomas. Concurrent with the promise and challenges in cancer …
-
Multi-Niche Human Bone Marrow On-A-Chip for Studying the Interactions of Adoptive Cell Therapies with Multiple Myeloma
… (MM), a cancer of bone marrow-resident plasma cells, is the 2nd-most common hematological malignancy. However, despite the advent of immunotherapies like chimeric antigen receptor (CAR) -T cells, which gained FDA approval in March 2021, relapse is nearly universally inevitable. The bone marrow …
-
Efficacy of Dual Cd19-Cd79B Car In B-Cell Malignancies
… CD19-targeting chimeric antigen receptor (CAR) T cell therapy. CD19 loss is a major cause of relapse and resistance after CD19 CAR T therapy. Dual antigen targeting could overcome resistance due to antigen escape and improve outcomes after CAR T cell therapy. We hypothesized that dual …
-
biological treatment options of multiple myeloma
… antibodies, Chimeric antigen receptor T cells, T cell engaging bispecific antibodies, antibody-drug conjugates along with steroids, and immunomodulatory therapies. Bortezomib, Carfilzomib, and Ixazomib are examples of proteasome inhibitors. Bortezomib is the predominant choice in …
-
Exploring Veto Activity: DNAM-1-CD155 Axis in Overcoming NK Cell-Mediated Allo-Rejection and Applications for CAR-T Cell Therapy
… Miller et al. defined veto activity, it enables cells to target host cytotoxic T lymphocyte (CTL) precursors specific to veto cells' antigens, selectively eliminating anti- donor T cell clones without inducing rejection. By leveraging this unique immune property, two key research aims were …
-
Finding Common Ground to Treat Primary and Metastatic Cancer: The Potential of Targeting Tumor Stroma
Primary carcinomas and metastases are complex organ-like structures composed of malignant parenchymal epithelial tissues and a desmoplastic stroma formed by accumulation of hematopoietic cells, mesenchymal stromal cells and extracellular matrix. The crosstalk between malignant epithelial cells and …
Page 1 of 2